DENVER — The interleukin-1 inhibitor anakinra has little to no effect on moderate to severe multisystem inflammatory syndrome in children, according to researchers.
Esra Akkoyun, MD, a pediatric infectious diseases fellow at the University of Texas Southwestern Medical Center, and colleagues reported their findings at the Pediatric Academic Societies Meeting.
Multisystem inflammatory syndrome in children (MIS-C) is a serious illness linked to SARS-CoV-2 infection.
“Given variability in therapies between centers, optimal regimens of immunomodulatory agents for MIS-C are unknown,”